A Study of LY2189265 in Japanese Patients With Type 2 Diabetes

NCT01001104 · Completed

Last updated 2026-05-28

This clinical trial tested the medication LY2189265 in Japanese adults with type 2 diabetes to see how it affected their blood sugar levels over 12 weeks.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 145 people

Who can join Ages 20–75 · all sexes

Timeline Started 2009-10 · est. completion 2010-12

Where 6 sites · Japan

What this study is testing ClinicalTrials.gov NCT01001104 ↗

Description as written by the study sponsor.

The main purpose of this study is to assess dose-response characteristics in Japanese patients with Type 2 Diabetes taking LY2189265 monotherapy.

Treatments tested

LY2189265 Drug

Administered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.
Placebo Drug

Administered by SC injection, QW for 12 weeks.

Main thing measured	Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01001104 ↗